Neurizon Therapeutics Limited (ASX:NUZ) Receives FDA Guidance on NUZ-001 IND Application
Neurizon Therapeutics Limited (ASX:NUZ) receives FDA guidance on its IND application for NUZ-001, requesting additional animal exposure data.
Category: Healthcare
Recce Pharmaceuticals (ASX:RCE) Reports Successful Phase II Trial Results
Recce Pharmaceuticals (ASX:RCE) reports successful Phase II trial of RECCE®327 Gel, advancing to Phase III for ABSSSI treatment.
The Calmer Co International Limited (ASX:CCO) Secures $2.6m FJD Loan for Navua Facility Acquisition
The Calmer Co (ASX:CCO) secures a $2.6m FJD loan for acquiring its Navua facility, enhancing its operational capabilities.
Avecho Biotechnology Limited (ASX:AVE) Addresses Recent Securities Trading
Avecho Biotechnology Limited (ASX:AVE) addresses recent securities trading, citing potential Phase III trial success and confirms compliance with ASX listing rules.
Wellnex Life Limited (ASX:WNX) Announces A$9 Million Commitments for AIM Dual Listing
Wellnex Life Limited (ASX:WNX) secures A$9 million in commitments for its AIM dual listing, enabling significant cost savings and supporting future growth.
Artrya Limited (ASX:AYA) Successfully Completes A$15 Million Placement
Artrya Limited (ASX:AYA) secures A$15 million through a two-tranche placement to advance its Salix® AI platform’s regulatory and commercial initiatives.
Imugene Limited (ASX:IMU) Reports 57% Complete Response Rate in CAR-T Trial
Imugene Limited (ASX:IMU) reports a 57% complete response rate in its Phase 1b CAR-T trial for relapsed/refractory DLBCL.
HealthCo Healthcare & Wellness REIT (ASX:HCW) Announces 1H FY25 Results
HealthCo Healthcare & Wellness REIT (ASX:HCW) reports a 5% growth in FFO/unit and DPU for 1H FY25, reaffirming its FY25 guidance.
AVITA Medical (ASX:AVH) Reports Q4 and FY 2024 Financial Results
AVITA Medical (ASX:AVH) reports a 30% revenue increase in Q4 and FDA approvals, setting the stage for significant growth in FY 2025.
Cochlear Limited (ASX:COH) Announces Half-Year 2024 Financial Results
Cochlear Limited (ASX:COH) reports a 5% revenue increase and an 8% interim dividend rise for the half year ended December 2024.